On-Demand Webinars

COVID-19: Navigating the Pandemic

  COVID-19 has spread to more than 60 countries, causing tens of thousands of illnesses and thousands of deaths. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are all racing to develop a treatment, a cure and a vaccine. In this Sanguine Speaker Series (3) virtual fireside chat, we will discuss: Response efforts to the current COVID-19 pandemic How does the race for the cure affect the hundreds of other drugs in development COVID-19’s potential impact on the global pharmaceutical market?

Sickle Cell Disease

A Novel Non-Covalent Modulator of Hemoglobin Improves Anemia and Reduces Sickling in a Mouse Model of Sickle Cell Disease. Speaker: Kelly M. Knee, PhD, Senior Principal Scientist, Rare Disease Researcher Unit, Pfizer Sickle cell disease is a severe genetic disorder caused by a single point mutation on the β-chain of adult hemoglobin (Hb A), β6 Glu→Val (Hb S).

COVID-19: Navigating the Pandemic

COVID-19 has spread to more than 60 countries, causing tens of thousands of illnesses and thousands of deaths. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are all racing to develop a treatment, a cure and a vaccine. Moderator Craig Lipset – Independent Advisor, Former Head of Clinical Innovation, Pfizer Transcript John: We would like to welcome you to the Sanguine Speaker Series Webinar on COVID-19; Navigating the Pandemic.

Biospecimen Donation: Personal Journey of a Family and Genetic Diagnostic Lab Advancing Biomedical Research

Author Sarah Gray shares her story of how she anonymously donated her infant son’s post-mortem tissue for biomedical research to some of the most prestigious scientific facilities in the country. Years later, after tracking down each donation, Sarah met with the research scientists that received the donations to learn how they are being studied in cutting-edge research for medical discoveries. One of these research scientists who received her son’s retinas is Dr.

Implementing AI: The Effects of AI in Drug Development

Join our distinguished Novartis speaker, Shruthi Bharadwaj, PhD as she speaks about her experience in AI including: With the costs to commercialize a new drug is dramatically increasing to over $2 billion, AI brings the opportunity to assist pharma companies to bring new drugs and therapies to the market faster. 

Simplifying Patient Participation

  Research depends on samples from patients and healthy volunteers. However, obtaining biospecimens from human subjects can be a challenge for researchers and patients alike. Home-based specimen collection directly connects patients to researchers, while alleviating the burden of travel to secondary sites.

Forging a Path for Early Clinical Development in Sickle Cell Disease

Distinguished Pfizer researchers David Beidler and Debra Pittman share their experience in Sickle Cell Disease including: Using longitudinal biomarker data from early clinical development decision in sickle cell disease (SCD) Building the patient perspective into clinical trials: development of the vaso-occlusive crisis (VOC) day endpoint through the use of the electronic patient-reported outcomes (ePRO) Bring it all together in ELIPSIS: a natural history study to evaluate longitudinal changes in ePRO, actigraphy, and biomarkers in SCD patients   Transcript Speaker 1: Today.

Leaders in Biobanking

  Sanguine partners with patients and leverages their health data to accelerate your research for their condition. By working together with patients directly, Sanguine is able to perform home visits and to easily retrieve medical records on their behalf. 500+ completed studies.